Sirolimus, Whole Blood
Use
Monitoring whole blood sirolimus concentration during therapy, particularly in individuals coadministered cytochrome P450 (CYP) 3A4 substrates, inhibitors, or inducers. Adjusting dose to optimize immunosuppression while minimizing toxicity. Evaluating patient compliance.
Special Instructions
Not provided.
Limitations
The assay is specific for sirolimus; it does not cross-react with cyclosporine, cyclosporine metabolites, tacrolimus, tacrolimus metabolites, or sirolimus metabolites. Results by liquid chromatography with detection by tandem mass spectrometry are approximately 30% less than by immunoassay. Blood drawn at other times will yield higher results than the recommended therapeutic range, which applies to trough specimens collected immediately before a dose.
New York Approved
Methodology
Mass Spectrometry (LC-MS/MS)
Biomarkers
LOINC Codes
- 29247-4 - Sirolimus Bld-mCnc
- 29247-4 - Sirolimus Bld-mCnc
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender top (EDTA)
Collection Instructions
Draw blood immediately before a scheduled dose. Do not centrifuge. Send whole blood specimen in original tube. Do not aliquot.
Causes for Rejection
Clotted specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 28 days |
| Refrigerated | 28 days |
| Frozen | 28 days |